Skip to content
Back to treatments
Transplant & Hematology~88% less than U.S.

Hemophilia Treatment

血友病治疗

Duration
Lifelong management with annual comprehensive reviews
Recovery
Ongoing prophylaxis, acute bleeds resolve in days
Average savings
88%
价格对比Price comparison

China versus the U.S.

China
$37,500
Range: $15,000–$60,000
United States
$300,000
Range: $100,000–$500,000
You save
88%
~$262,500 per procedure
China clinical rate
$15,000 – $60,000
$37,500
United States
$100,000 – $500,000
$300,000
You save
~88%
$262,500 per procedure

Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.

关于About this treatment

What the procedure involves.

Comprehensive hemophilia management including prophylactic factor replacement, extended half-life products, non-factor therapies (emicizumab), and gene therapy evaluation. China's hemophilia treatment centers provide multidisciplinary care addressing bleeding prevention, joint protection, and emerging curative approaches. Significant cost advantages for factor concentrates and bispecific antibody therapies.

流程Procedure steps

Step by step.

  1. 01

    Comprehensive Assessment

    Factor level testing, inhibitor screening, joint assessment with MRI, and genotyping for severity classification

    Duration · 2-3 days
  2. 02

    Prophylaxis Initiation

    Selection and initiation of optimal prophylactic regimen (standard or extended half-life factor, or emicizumab)

    Duration · 2-4 weeks
  3. 03

    Joint Health Program

    Physiotherapy, joint preservation strategies, and assessment for synovectomy or joint replacement if needed

    Duration · Ongoing
  4. 04

    Gene Therapy Evaluation

    Assessment for emerging gene therapy trials and novel treatments with potential for functional cure

    Duration · Consultation
Benefits
  • Access to modern prophylaxis at significantly reduced cost
  • Emicizumab and extended half-life products available
  • Comprehensive multidisciplinary hemophilia center care
  • Potential access to gene therapy clinical trials
Considerations
  • Inhibitor development against replacement factors
  • Breakthrough bleeding despite prophylaxis
  • Joint damage if treatment delayed or inadequate
  • Gene therapy still experimental with uncertain long-term outcomes
下一步Next step

Ask the AI for hospitals that handle hemophilia treatment.

Ask AIRequest consultation

Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.